LRRK2 Modulating Compounds for Selective Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's disease and other conditions associated with LRRK2 dysfunction lack selective and effective compounds that modulate LRRK2 activity without affecting other kinases like JAK2.
Innovation Solution
Development of specific compounds, including those of the formula I and II, which are designed to selectively modulate LRRK2 activity, offering potential therapeutic benefits for a range of diseases including Parkinson's, Alzheimer's, cancers, and inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to modulate LRRK2 activity, then therapeutic effectiveness for Parkinson's disease is improved, but selectivity over other kinases like JAK2 deteriorates
Solution Approach 1:
The patent applies local quality by designing specific molecular features at particular positions of the kinase inhibitor structure. The compounds contain specific substituent patterns at defined positions (R1-R6 groups) that create localized interactions with LRRK2's unique binding pocket, enabling selective modulation of LRRK2 while minimizing effects on other kinases like JAK2
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, chain lengths, and functional groups in the kinase inhibitor molecules. These parameter modifications allow optimization of binding affinity for LRRK2 while maintaining selectivity, resolving the contradiction between effectiveness and off-target effects
2Adaptability or versatility
If broad-spectrum kinase inhibitors are used, then multiple disease conditions may be treated, but specificity for LRRK2-mediated diseases deteriorates
Solution Approach 1:
The patent applies universality by designing a core molecular scaffold that can selectively target LRRK2 across multiple disease contexts including Parkinson's disease, cancer, and inflammatory disorders. The compounds maintain their primary selectivity for LRRK2 while being applicable to various LRRK2-mediated conditions, achieving versatility without sacrificing precision
Data Source
AI summary
Specific Compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein m, X, R, R2, R3, R, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.